T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

Conditions

Diabetes Mellitus - Type 1 | Diseases of the Endocrine System

Phase I

What is the purpose of this trial?

The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.

  • Trial with
    University of California, San Francisco
  • Start Date
    05/24/2017
  • End Date
    07/30/2021
Trial Image

For more information about this study, contact:

Linda Ryall

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    02/22/2018
  • Study HIC
    #1607018090